Pharmacotherapy of masticatory system dysfunction.
The decision to use drugs systemically in the management of mandibular dysfunction must be made with consideration of the information summarized in this report. It has been shown that pharmacotherapy may be effective. It has also been demonstrated that systemic pharmacotherapy frequently produces side effects which are occasionally severe. The clinician must decide on the appropriateness of therapy with the knowledge that many other conservative measures may also have excellent success rates and that pharmacotherapy is likely to be palliative rather than curative.
D000772:Anesthesia, Local; D000928:Antidepressive Agents / Q000627:therapeutic use; D003975:Diazepam / Q000627:therapeutic use; D005018:Ethyl Chloride / Q000627:therapeutic use; D006801:Humans; D008409:Mastication; D008620:Meprobamate / Q000627:therapeutic use; D009966:Orphenadrine / Q000627:therapeutic use; D010919:Placebos; D013706:Temporomandibular Joint Dysfunction Syndrome / Q000188:drug therapy* / Q000523:psychology
D000928:Antidepressive Agents; D010919:Placebos; D005018:Ethyl Chloride; D008620:Meprobamate; D009966:Orphenadrine; D003975:Diazepam